Dinçer Büşra Tetik, Usta Ayşe Merve, Kural Alev, Helvacı Nazlı, Uçar Ahmet, Urgancı Nafiye
Department of Pediatrics, Sisli Hamidiye Etfal Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
Department of Pediatrics, Division of Pediatric Gastroenterology, Sisli Hamidiye Etfal Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
BMC Pediatr. 2024 Dec 23;24(1):834. doi: 10.1186/s12887-024-05327-4.
The incidence of non-alcoholic fatty liver disease (NAFLD) is increasing with obesity, and it is believed that the ongoing low-grade inflammation in obesity and alterations in the enterohepatic axis contributing this process. This study aimed to determine the role of fecal calprotectin (FC) as inflammatory biomarker in obesity and NAFLD.
Between November 2022-August 2023, 31 obese and 10 healthy adolescents aged between 10 and 18 years enrolled in this prospective controlled study. Body mass index higher than 2 standard deviation is considered as obesity. Obese adolescents were divided into two subgroups: obese adolescents (n = 11) and Obese + NAFLD group (n = 20). NAFLD diagnosis was made with biochemical analysis or ultrasonography. FC levels and laboratory parameters analyzed in study group, while only FC samples taken from control group. Anthropometric and laboratory parameters were compared between groups. This study was registered in ClinicalTrials.gov (NCT06229184).
The median (IQR P25-75) FC levels in the obese + NAFLD, obese and the healthy controls were 136.23 (43.36-332.04), 61.77 (29.70-285.92) and 38.95 (27.59-50.52) µg/g feces, respectively (p = 0.018). Subgroup analyses revealed that the significant difference was between the obese + NAFLD group and the control group (p = 0.02), while no significant differences were observed between the control and obese groups, or between the obese and obese + NAFLD groups. FC positivity rates were 20% (n = 2) in the control group, 54.5% (n = 6) in the obese group, and 75% (n = 15) in the Obese + NAFLD group (p = 0.018).
FC is significantly higher in obese adolescents compared to healthy peers, but no significant difference was observed between obese and obese + NAFLD groups. Further studies needed on this subject.
This trial is registered in ClinicalTrials.gov (Trial registration number [ClinicalTrials.gov ID] NCT06229184).
非酒精性脂肪性肝病（NAFLD）的发病率随着肥胖率的上升而增加，人们认为肥胖过程中持续存在的低度炎症以及肠肝轴的改变促成了这一过程。本研究旨在确定粪便钙卫蛋白（FC）作为肥胖和NAFLD炎症生物标志物的作用。
在2022年11月至2023年8月期间，31名年龄在10至18岁之间的肥胖青少年和10名健康青少年参与了这项前瞻性对照研究。体重指数高于2个标准差被视为肥胖。肥胖青少年被分为两个亚组：肥胖青少年组（n = 11）和肥胖 + NAFLD组（n = 20）。通过生化分析或超声检查进行NAFLD诊断。在研究组中分析FC水平和实验室参数，而对照组仅采集FC样本。比较各组之间的人体测量和实验室参数。本研究已在ClinicalTrials.gov（NCT06229184）注册。
肥胖 + NAFLD组、肥胖组和健康对照组的FC水平中位数（IQR P25 - 75）分别为136.23（43.36 - 332.04）、61.77（29.70 - 285.92）和38.95（27.59 - 50.52）μg/g粪便（p = 0.018）。亚组分析显示，肥胖 + NAFLD组与对照组之间存在显著差异（p = 0.02），而对照组与肥胖组之间、肥胖组与肥胖 + NAFLD组之间未观察到显著差异。FC阳性率在对照组为20%（n = 2），肥胖组为54.5%（n = 6），肥胖 + NAFLD组为75%（n = 15）（p = 0.018）。
与健康同龄人相比，肥胖青少年的FC水平显著更高，但肥胖组与肥胖 + NAFLD组之间未观察到显著差异。需要对此主题进行进一步研究。
本试验已在ClinicalTrials.gov注册（试验注册号 [ClinicalTrials.gov ID] NCT06229184）。
